277 related articles for article (PubMed ID: 30983153)
21. Gypenoside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB, AKT, and MAPK signaling pathways.
Han J; Gao W; Su D; Liu Y
J Cell Biochem; 2018 Sep; 119(9):7310-7318. PubMed ID: 29797602
[TBL] [Abstract][Full Text] [Related]
22. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
Chen G; Xu Q; Dai M; Liu X
Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of RIPK1/RIPK3 ameliorates osteoclastogenesis through regulating NLRP3-dependent NF-κB and MAPKs signaling pathways.
Liang S; Nian Z; Shi K
Biochem Biophys Res Commun; 2020 Jun; 526(4):1028-1035. PubMed ID: 32321638
[TBL] [Abstract][Full Text] [Related]
24. Isobavachin attenuates osteoclastogenesis and periodontitis-induced bone loss by inhibiting cellular iron accumulation and mitochondrial biogenesis.
Li T; Du Y; Yao H; Zhao B; Wang Z; Chen R; Ji Y; Du M
Biochem Pharmacol; 2024 Jun; 224():116202. PubMed ID: 38615917
[TBL] [Abstract][Full Text] [Related]
25. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
[TBL] [Abstract][Full Text] [Related]
26. Dehydrocostus lactone attenuates osteoclastogenesis and osteoclast-induced bone loss by modulating NF-κB signalling pathway.
Hu B; Wu F; Shi Z; He B; Zhao X; Wu H; Yan S
J Cell Mol Med; 2019 Aug; 23(8):5762-5770. PubMed ID: 31225720
[TBL] [Abstract][Full Text] [Related]
27. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effects of obovatol on osteoclast differentiation and bone resorption.
Kim HJ; Hong JM; Yoon HJ; Kwon BM; Choi JY; Lee IK; Kim SY
Eur J Pharmacol; 2014 Jan; 723():473-80. PubMed ID: 24334279
[TBL] [Abstract][Full Text] [Related]
29. Protective Effect of Ciclopirox against Ovariectomy-Induced Bone Loss in Mice by Suppressing Osteoclast Formation and Function.
Ihn HJ; Lim J; Kim K; Nam SH; Lim S; Lee SJ; Bae JS; Kim TH; Kim JE; Baek MC; Bae YC; Park EK
Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361069
[TBL] [Abstract][Full Text] [Related]
30. Pectolinarigenin prevents bone loss in ovariectomized mice and inhibits RANKL-induced osteoclastogenesis via blocking activation of MAPK and NFATc1 signaling.
Xiao Y; Li K; Wang Z; Fu F; Shao S; Song F; Zhao J; Chen W; Liu Q; Xu J
J Cell Physiol; 2019 Aug; 234(8):13959-13968. PubMed ID: 30633330
[TBL] [Abstract][Full Text] [Related]
31. Helvolic acid attenuates osteoclast formation and function via suppressing RANKL-induced NFATc1 activation.
Chen K; Yuan Y; Wang Z; Song D; Zhao J; Cao Z; Chen J; Guo Q; Chen L; Tickner J; Xu J
J Cell Physiol; 2019 May; 234(5):6477-6488. PubMed ID: 30341897
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
33. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
[No Abstract] [Full Text] [Related]
34. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
35. Ruboxistaurin maintains the bone mass of subchondral bone for blunting osteoarthritis progression by inhibition of osteoclastogenesis and bone resorption activity.
Pang C; Wen L; Lu X; Luo S; Qin H; Zhang X; Zhu B; Luo S
Biomed Pharmacother; 2020 Nov; 131():110650. PubMed ID: 32882584
[TBL] [Abstract][Full Text] [Related]
36. NADPH oxidase gp91
Kang IS; Kim C
Sci Rep; 2016 Nov; 6():38014. PubMed ID: 27897222
[TBL] [Abstract][Full Text] [Related]
37. Isoimperatorin attenuates bone loss by inhibiting the binding of RANKL to RANK.
Li H; Deng W; Qin Q; Lin Y; Liu T; Mo G; Shao Y; Tang Y; Yuan K; Xu L; Li Y; Zhang S
Biochem Pharmacol; 2023 May; 211():115502. PubMed ID: 36921635
[TBL] [Abstract][Full Text] [Related]
38. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
[TBL] [Abstract][Full Text] [Related]
39. Toddalolactone protects against osteoarthritis by ameliorating chondrocyte inflammation and suppressing osteoclastogenesis.
Xu Y; Xue S; Zhang T; Jin X; Wang C; Lu H; Zhong Y; Chen H; Zhu L; Ma J; Sang W
Chin Med; 2022 Feb; 17(1):18. PubMed ID: 35123541
[TBL] [Abstract][Full Text] [Related]
40. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
